Immunology and Hereditary Autoinflammatory Diseases Scientist
Archived on January 28, 2026. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 12:00 PM EST
- Posted
- January 9, 2026
- Notice type
- Presolicitation
- Set-aside
- Total Small Business Set-Aside (FAR 19.5)
- NAICS
- 541715: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Agency
- Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH
Notice details
- Office
- NATIONAL INSTITUTES OF HEALTH NICHD
- Last updated
- Nov 4, 2026
- First published
- Last updated on SAM.gov
Identifiers
- Solicitation number
- 75N94026Q00028
- Notice ID
- 86062bc503ea43908751fbb383888d7d
Description
INTRODUCTION
THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME).
The National Institute of Child Health and Human Development (NICHD), Office of Acquisitions (OA) on behalf of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) intends to award a purchase order without providing for full and open competition for Immunology and Hereditary Autoinflammatory Diseases Scientist from Edwan LLC.
NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE
The intended procurement is classified under NAICS code 541715 with a Size Standard of 1000 employees.
REGULATORY AUTHORITY
The resultant contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2025-06 effective October 1, 2025.
This acquisition is conducted under the procedures as prescribed in FAR Subpart 13.106-1(b).
STATUTORY AUTHORITY
This acquisition is conducted under the authority of 41 U.S.C. 1901 – Simplified Acquisition Procedures.
DESCRIPTION OF REQUIREMENT
BACKGROUND
The Biomedical and Metabolic Imaging Branch (BMIB) focuses on developing noninvasive imaging approaches with high spatial (micro-millimeter) and temporal (milliseconds) resolution that allow multi-organ evaluation and analysis to better understand the interplay between atherogenesis and metabolic syndrome in humans. Patients with rare genetic mutations such as hyper immunoglobulin E (Job's) syndrome (immune system and coronary arteries), Turner's syndrome (genetics and vascular disease), lipodystrophy (metabolic dysfunction and cardiovascular disease), or HIV infection (inflammation and coronary disease), share many of the metabolic and immunological dysregulations encountered in multi-organ disease subjects inclusive of atherogenesis. The goal has been to isolate and understand the effects of these defects and the early events that signal atherosclerosis.
In order to accomplish the goals of this program, The National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), BMIB has a requirement to obtain services of a scientist with extensive expertise in innate immunology and hereditary autoinflammatory diseases with demonstrated understanding of, and ability to apply principles, concepts, practices and standards associated with patient sample testing in a laboratory setting. The scientist must demonstrate experience and understanding of techniques directly applicable to the Biomedical and Metabolic Imaging Branch research (tissue culture, molecular and cellular biological techniques such as PCR, flow cytometry, IHC, etc.) and must be self-motivated and driven to achieve milestones and exceed goals with minimal direction. Furthermore, they must possess a PhD with 15+ years of demonstrated expertise in immunology and/or inflammation research.
CONTRACTOR REQUIREMENTS
The contractor must have:
- PhD with 15+ years of directly relevant experience in immunology, or inflammation.
- Proficiency in T cell culture, multicolor Flow Cytometry, RNA-seq, western blotting, q-PCR, multiplex ELISA, mRNA isolation, T cell isolation, cell assay development, mouse handling/ organ isolation is required.
- Expertise in lentiviral production, synthetic biology, lentiviral vector design desired.
- Expertise in exosome purification and characterization.
- Knowledge of standard Human T cell isolation & in vitro culture techniques is required.
- Possess experience using autoimmune and inflammatory disease mouse and rabbit models.
- Good understanding of immune signaling pathways and interest in metabolomics.
- Ability to contribute creatively and strategically to in vitro assay design, optimization and derive actionable biological conclusions.
- Ability to define and implement critical studies needed to support hypothesis-based research.
- Ability to write protocols and study reports, produce and maintain accurate records.
- Expertise with data analysis software such as Excel and Graphpad Prism
- Strong verbal and written communication skills.
- Ability to synthesize complex scientific problems into a strategy and tactics.
- Familiarity with both Microsoft and Mac operating systems, including PowerPoint, Excel, Word, Adobe Photoshop and Access.
- Excellent interpersonal, analytical, organizational and time management skills.
The contractor shall deliver scientific data and results and implement the following:
- Tissue processing and purification of immune cells, in vitro cell based bioassay development, tissue cell culture (primary mouse and human cells and cell lines)
- Multicolor flow cytometry (FACS), and ELISA assays
- Basic molecular biology techniques (cloning, viral tranductions, etc.)
- Analyze biological data using FlowJo, Microsoft Excel, and GraphPad Prism
- Interpret, analyze and present data; work in fast-paced, result oriented research environment
- Contribute to project advancement by developing new methods or technologies and troubleshooting existing protocol
- Write protocols and study reports, produce and maintain accurate records
- Prepare manuscripts for journal publications
The contractor shall:
- Drive discovery and translational research aimed at identifying, characterizing, and interpreting results for novel diagnosis for inflammatory diseases. The candidate must be able to create their own research plans with minimum support from the principal investigator. The candidate must be able to run research plans independently. Weekly/as needed meetings shall be held to evaluate the work and provide directions for next steps.
- Define and implement critical studies needed to support hypothesis-based research. The candidate’s progress shall be parodically evaluated and the candidate shall be provided with feedback and directions.
- Make contributions to scientific literature and conferences through publication and presentation of research results. The candidate shall be evaluated based on preparing manuscripts and abstracts for scientific publications.
- Identify and evaluate a wide variety of in vitro assays to test immunological, metabolic, and various disease mechanisms.
- Contribute creatively and strategically to in vitro assay design, optimization, and derive actionable biological conclusions.
- Perform assay development, qualification and validations as needed.
- Conduct cell-based assays including, but not limited to, ELISA and Flow Cytometry.
- Separate, isolate and cryopreserve primary cells peripheral blood mononuclear cells (PBMCs).
- Organize data prior to scientific publication submission. The data shall be reviewed and evaluated by the principal investigator.
- Ensure lab maintenance activities and equipment calibration are performed according to schedule.
- Ensure lab maintenance activities and maintain a clean and safe lab environment.
ORDER TYPE
This purchase order will be a firm fixed price.
PERIOD OF PERFORMANCE AND PAYMENT BREAKDOWN
The period of performance for this order is:
Base period: 1/20/2026 to 1/19/2027
Option period 1: 1/20/2027 to 1/19/2028
Payment shall be made monthly in arrears.
The contractor shall work 40 hours per week, Monday through Friday, totaling 2080 hours per year.
CLOSING STATEMENT
Extensive expertise in innate immunology and hereditary autoinflammatory diseases is vital to the study of the relationship between atherosclerosis and obesity and other metabolic disorders. This is an ongoing project, with several ongoing experiments. All of these experiments are highly complex in nature and require great attention to technical details.
Edwan LLC possesses extensive expertise in innate immunology and hereditary autoinflammatory diseases, which is vital to the study of the relationship between atherosclerosis and obesity and other metabolic disorders. The Biomedical and Metabolic Imaging Branch has been unable to locate on the market other vendors with this expertise and knowledge. In addition, this is an ongoing project that requires specific knowledge of the history of the development of each experiment and the thought process that led to each conclusion. Thus, these unique capabilities can’t be easily replicated in other vendors.
This is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties’ bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Unique Entity Identifier (UEI), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.
A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement.
All responses must be received by Tuesday, January 13, 2026 at 12:00 PM EST. Responses must be submitted via email to Kimesha Leake, Contracting Officer at Kimesha.leake@nih.gov
All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Contracting Officer
Primary Contact
Documents
No documents available.
Lifecycle
- 3Version 3PresolicitationArchivedCurrent
Immunology and Hereditary Autoinflammatory Diseases Scientist
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
AREMP AND WATER SAMPLE ANALYSIS | 57% | Awarded | Open |
This is a combined synopsis/solicitation for Systems Engineering and Technical Assistance (SETA) to provide the Office of the Assistant Secretary for Space Acquisition and Integration (SAF/SQ) with technical, space acquisition, and support advisory and assistance services for the period of five years consisting of a base plus four one-year option periods. The Government intends to award a Firm Fixed-Price (FFP) contract resulting from this solicitation. This solicitation document incorporates provisions and clauses are those in effect through Federal Acquisition Circular 2025-06, Defense Federal Acquisition Regulation Supplement Changes effective 10 November 2025, and Department of the Air Force Federal Acquisition Regulation Supplement Changes effective 16 October 2024. | 51% | Combined Synopsis | 03/10/2026 |
NASA/GSFC has a requirement for Electrical Systems Engineering Services and related services to the Engineering and Technology Directorate (ETD) as required, for the study, design, systems engineering, development, fabrication, integration, testing, verification, and operations of space flight, airborne, and ground system hardware and software, including development and validation of new technologies to enable future space and science missions. NASA/GSFC intends to increase the contract ceiling by $75.6M and extend the contract’s period of performance on a sole source basis to acquire the services from Science Systems and Applications, Inc. (SSAI) to allow for the continuation of mission critical services under the ESES III contract. This extension will allow for continued contract performance and continuation of mission critical services under the ESES III contract. As such NASA/GSFC intends to extend the current contract effective ordering period by a base period of 4 months and if needed, two additional option periods of 4 months each, totaling a potential contract extension of up to one (1) year (through December 8, 2025), by which time the follow-on, competitive contract is expected to be awarded. This is a Cost-Plus-Award-Fee (CPAF), Single-Award Indefinite Delivery Indefinite Quantity (IDIQ) contract, 80GSFC18C0120. The rationale supporting this sole source award to SSAI is in accordance with 10 U.S.C 2304(c)(1), as implemented by FAR 6.302-1, only one responsible source and no other supplies or services will satisfy agency requirements and is based on the nature of the work to be performed, and the fact that NASA/GSFC currently has a competitive follow-on procurement underway. The Government does not intend to acquire a commercial item using FAR Part 12. Interested organizations may submit their capabilities and qualifications to perform the effort electronically via email to Sarah Odom (Sarah.Odom@nasa.gov) not later than 4 PM EDT on October 25, 2024. Such capabilities/qualifications will be evaluated solely for the purpose of determining whether or not to conduct this acquisition on a competitive basis. A determination by the Government not to compete this acquisition on a full and open competition basis, based upon responses to this notice, is solely within the discretion of the Government. NASA Clause 1852.215-84, Ombudsman, is applicable. The Center Ombudsman for this acquisition can be found at : https://www.hq.nasa.gov/office/procurement/regs/Procurement-Ombuds-Comp-Advocate- | 51% | Pre-Solicitation | 10/25/2024 |
Amendment 1 - This amendment provides questions to vendor clarifying questions and adds a revised RFQ (updated per vendor questions) and revised SOW (Task Order 2 updated). All changes to the revised documents are in red text. The goal of this acquisition is to acquire a contractor that offers a full range of (1) clinical research services, including clinical research management, statistical design and analysis, protocol development and data management, clinical site management, pharmacovigilance services, quality assurance, and regulatory affairs support; (2) specialty services, including DSMB services; (3) analytical solutions, including bioinformatics, and (4) integrated clinical trial management through an organized system of tracking clinical trials. The contractor should be capable of providing these services, as required under the individual task orders, to support NHGRI clinical research protocols and related activities within the scope of this IDIQ contract. The contractor should be capable assigning qualified personnel with experience in clinical trial design and regulatory requirements, especially as relates to studies of rare diseases, genetic conditions, gene therapy (including via AAV9 vectors), and pediatric as well as adult populations, as applicable to individual task orders. | 49% | Combined Synopsis | 11/13/2026 |
INTRODUCTION: The National Institute of Allergy and Infectious Diseases (NIAID), one of 27 institutes of the NIH, an agency within the Department of Health and Human Services (DHHS); conducts and supports research to understand, treat, and ultimately prevent the myriad infectious, immunologic, and allergic diseases that threaten the health and longevity of human lives.Through a variety of research grants and contracts, NIAID’s Division of Microbiology and Infectious Diseases (DMID) specifically supports extramural research to develop new medical interventions against infectious disease threats to include drug-resistant pathogens. NIAID/DMID intends to use this BAA to help address goals articulated in a number of strategic plans, such as in the Public Health Emergency Medical Countermeasures Enterprise Strategy and Implementation Plan (https://aspr.hhs.gov/PHEMCE/2024-PHEMCE-SIP/Pages/default.aspx), as well as current prioritized antimicrobial resistant threats identified by national death and infection estimates as determined by the Centers for Disease Control and Prevention’s (CDC) to prevent and control antimicrobial resistance (https://www.cdc.gov/antimicrobial-resistance/data-research/threats/index.html). In addition, NIAID/DMID intends to use this BAA to encourage projects that align with the NIH priorities of enhancing rigor & reproducibility, improving biosafety and biosecurity, and the use of complementary non-animal testing methods where appropriate. This Broad Agency Announcement (BAA) is soliciting proposals to advance the research and development of promising candidate therapeutics, vaccines, and diagnostics for infectious diseases in each of three (3) Research Areas described below and more thoroughly discussed in the attached BAA Solicitation. An offeror should carefully review the content of the BAA Solicitation No. HHS-NIH-NIAID-BAA2026-1 for the comprehensive information regarding all requirements, the technical objective of each Research Area of this BAA Solicitation, instructions regarding the proposal submission, and a description of the evaluation and award process. Please note, due to the competitive nature of the BAA Solicitation, the NIAID is unable to offer advice or feedback regarding an offeror’s specific technical approach. Offerors should exercise their professional judgment when compiling their proposals in line with the requirements and specifications of the BAA Solicitation. Research Area 001 - Vaccine Candidates: The objective is to develop vaccine candidates through an early phase clinical trial that use a needle free (i.e., alternative to classical needle and syringe, see below for description) route of delivery to protect against infections caused by viral pathogens that include but are not limited to respiratory and vector borne viruses. The scope of this vaccine research area includes the preclinical development of a needle free vaccine candidate, IND enabling studies, limited process development, Good Manufacturing Practice (GMP) compliant manufacturing, regulatory submissions to the U.S. Food and Drug Administration (FDA) and conduct of a Phase 1 or early Phase 2 clinical trial. The scope of work must include a clinical trial. Offerors must propose a single vaccine candidate for protection against a specific viral pathogen. The vaccine candidate may provide a breadth of protection against other viral strains or viruses. A strong justification is required to support (1) the proposed vaccine antigen and platform for the disease indication, (2) the use of a clinically relevant adjuvant (if needed), and (3) a clinically relevant needle free route of delivery. Research Area 002 - Therapeutic Candidates: The objective is to develop safe, effective, new therapeutic products that will improve patient outcomes against serious infectious diseases for which there are no approved therapeutics, or for those that are refractory to treatment despite appropriate antimicrobial therapy or due to pathogen resistance. Infectious diseases caused by the following viruses, bacteria and fungi pathogens are targeted: Viral hemorrhagic fever viruses (e.g., EBOV, SUDV, MARV, LASV, hantavirus) https://www.cdc.gov/viral-hemorrhagic-fevers/about/index.html Encephalitic paramyxoviruses (e.g. hendra virus, nipah virus) Picornaviruses (broad spectrum approaches that include EV68, EV70 and coxsackie virus) At least two of the following (i.e., addressed with a broad spectrum antimicrobial): susceptible and carbapenem-resistant Enterobacteriaceae (CRE), susceptible and multidrug resistant (MDR) Pseudomonas aeruginosa, and susceptible and Carbapenem-resistant Acinetobacter (CRAB), with potential to improve patient outcomes in the clinic; Candida auris, Cryptococcus spp., Aspergillus fumigatus, and/or Mucorales Adjunct medical interventions to support or enhance effectiveness of antimicrobial agents to address underlying pathology that is not resolved after clearance of pathogens, may be considered. Important notice to Offerors: For this Research Area, “therapeutic” activity means curing disease by eliminating or substantially reducing infective pathogens by administering antimicrobial pharmaceutical agents, with or without a host-directed therapy. Additionally, proposed therapeutic products should consider the impact on a healthy microbiome. Preventative treatments are not included in the scope of this Research Area. A therapeutic candidate refers to an advanced lead series, preclinical candidates, or a clinical candidate, that is a new chemical entity. This includes small molecules, natural products, nucleosides, or peptides of </= 40 amino acids, monoclonal antibodies, nanobodies, nanobody conjugate/fusion products, microbiome-based therapeutics or bacteriophages. Research Area 002 will support lead optimization, pre-clinical Investigational New Drug (IND) enabling studies, and Phase 1 clinical trials (or proof of concept Phase 2 clinical trials) of lead candidates with demonstrated therapeutic activities. This includes support for traditional, novel (e.g., small molecules) and non-traditional (e.g., including but not limited to phage, and host-directed) therapeutics for infectious diseases where patients lack effective interventions, as well as therapeutics that promote host-mediated resolution of disease. The scope of support differs depending on the developmental stage of the project being proposed, which is further discussed in the BAA Solicitation. Research Area 003 - In Vitro Diagnostics The objective of Research Area 003 is to develop innovative, technology platforms that will speed detection and identification of infectious viruses covering a broad panel of virus families, including viruses causing acute infections as well as those causing chronic infections. Technology platform innovation to achieve faster actionable sequencing results (approaching 2 hr) direct from primary clinical specimens, as well as more accessible workflow and configuration (i.e., point-of-care) are preferred. Furthermore, full sample-to-answer platform solutions are preferred. The system should accept specimen volumes from 0.5 to 5 milliliters (mL). The system should include nearly full automation (little or no hands-on activity after specimen has been loaded into system). Sample preparation components of the system should yield sufficient analyte recovery from a starting titer of 10-100 genomic copies per mL of biofluid for downstream analysis, including detection, identification, and characterization of the nucleic acid material. Innovations during platform development might include, for example: Automated sample prep for high recovery from low pathogen load. Faster specimen-to-answer for total test time <2 hours. Broad viral pathogen detection capability, covering one or more members of the priority pathogen families (see below). Targeted, or even untargeted pathogen detection and identification via long-read sequencing or other detection methods. Multiple specimen throughput per run for reduced cost. Analytical sensitivity approaching 5-50 genome copies per mL of starting biofluid. Assay reconfigurability to respond rapidly to a novel pathogen in days or weeks rather than months (i.e., agnostic diagnostic solution). Priority Pathogens The diagnostic test system must detect analytes from at least one, and preferably several, of the following agents and markers: Arenaviridae (e.g., Lassa virus) Phenuviridae (e.g., Rift Valley fever virus) Peribunyayviridae (e.g., Oropouche virus) Hantaviridae (e.g., Hantavirus) Nairoviridae (e.g., Crimean Congo Hemorrhagic fever virus) Filoviridae (e.g., Sudan virus, Ebola virus, Marburg virus) Flaviviridae (e.g., Hepatitis C virus, West Nile Virus) Paramyxoviridae (e.g., Nipah virus) Togaviridae (e.g., Chikungunya virus) Picornaviridae (e.g., Enterovirus) PROPOSAL SUBMISSION: Proposals Due Date and Time – December 8, 2026, 3:00 PM Eastern Time For this solicitation, the NIAID requires proposals to be submitted online via the NIAID electronic Contract Proposal Submission (eCPS) website. Submission of proposals by any other method is not permitted. For directions on using eCPS, go to the website: https://ecps.nih.gov and thenclick on "How to Submit." | 48% | Solicitation | 12/08/2026 |
Additional Details
Solicitation Number
75N94026Q00028
Archive Date
Jan 28, 2026
Office Address
BETHESDA, MD, 20817